Liver
Magnetic resonance imaging (MRI) using gadoxetate (Primovist; Bayer, Osaka, Japan) enhancement was performed for the liver lesion; an ill-defined, irregularly shaped mass of 7 cm in diameter was found in the right hepatic lobe, showing slight T1 and T2 prolongation, diffusion restriction, and vessel penetration sign, along with several satellite lesions. The central part of the mass showed delayed enhancement on the 
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FDG uptake is evident in the liver mass (arrowhead), right paraspinal muscle, and porta hepatis lymph nodes (arrows). The maximum standardized uptake value of the liver mass was 8.59. dynamic phase, and also faint uptake of gadoxetate on the hepatobiliary phase (Fig. 1) . Fluorine 18 fluorodeoxyglucose ( 18 FDG) positron emission tomography-computed tomography (CT) showed strong uptake of the radioisotope at the liver mass, with the maximum standardized uptake value of 8.59 (Fig. 2) . Multiple lesions of similar 18 FDG uptake were found in the cervical and abdominal lymph nodes and musculoskeletal system (Fig. 2) . Clinicoradiologically, malignant lymphoma was strongly suspected, and percutaneous needle biopsies were performed for the cervical lymphadenopathy once, and for the multiple liver masses twice; however, only inflammatory to fibrogranulomatous tissues, or epithelioid cell granulomas were found, with no evidence of malignant cells. A possibility of sarcoidosis was considered, which was denied by the absence of uveitis, typical pulmonary or myocardiac lesions, and negative angiotensin converting enzyme. A conservative therapy using 30 mg prednisolone per day was given, but follow-up dynamic CT using iodine contrast medium (Iomeron 350, Eisai Co Ltd, Tokyo) obtained 3 months after admission revealed apparent disease progression: the liver mass increased in size, showing prominent delayed central enhancement that suggested presence of abundant fibrous stroma, without evident necrosis (Fig. 3) . To make a definitive diagnosis, surgical biopsy was performed for one of the liver nodules located at the edge of the lateral segment and intraperitoneal enlarged lymph nodes. Microscopically, the specimens revealed a small number of Hodgkin cells and Reed-Sternberg cells scattered in the abundant fibrogranulomatous background tissue (Fig. 4) . A final diagnosis of secondary hepatic Hodgkin lymphoma (HL), mixed cellularity type, was made. The patient was given twelve courses of chemotherapy using adriamycin, bleomycin, vinblastine, and dacarbazine, and showed complete response 10 months later.
Discussion
Hodgkin disease, or HL, is a relatively rare entity, accounting for less than 10% of all malignant lymphoma [1e4]. Hepatic lymphoma is usually non-Hodgkin diffuse large B-cell lymphoma [1] , and its radiological features have been well described [2, 3, 5] . They may exhibit various imaging findings; however, typically show relatively homogeneous mass with mild T1 and T2 prolongation, strong diffusion restriction, mild enhancement, and vessel penetration sign [2, 3, 5] . On the other hand, primary hepatic HL is extremely rare, whereas secondary hepatic involvement by HL is relatively commonly encountered, with an incidence of around 20% of all HL [1e4], and little has been reported on its radiological features [6] . Because HL is very chemo-and radio-sensitive, early precise diagnosis benefits patients' prognosis [1, 4] . In our case, several imaging features were similar to those of non-Hodgkin lymphoma (NHL), as previously reported. However, one peculiar finding was a delayed enhancement without evident necrosis, which was observed in the central part of the main liver mass both on MR imaging and dynamic CT (Figs 1, 3) , which has never been described in the literature in hepatic HL.
Histologically, HL is characterized by the presence of Hodgkin cell and Reed-Sternberg cell within abundant fibrogranulomatous background tissue [1e6]. It has been well known that presence of fibrous stroma results in delayed enhancement when extracellular contrast medium is given [7, 8] . Because iodine contrast medium for CT is a purely extracellular agent, whereas gadoxetate is half extracellular and half tissue-specific agent [9] , it is reasonable that this delayed enhancement was more prominent on CT rather than on MRI in our case. According to the previous study in which HL and NHL were compared in the cervical lymphomatous nodal lesions, HL showed significantly higher density than NHL on the delayed phase of CT after iodine contrast medium administration [10] . Findings in our case is consistent with this observation, and we consider that this delayed enhancement without evident necrosis could be a sign to distinguish HL from NHL in the liver as well.
As for the definitive diagnosis of HL, verifying the presence of Hodgkin cell and Reed-Sternberg cell is essential, but it has been known that it is occasionally difficult to obtain sufficient amount of tissue with percutaneous needle biopsy, because the number of Hodgkin cells and Reed-Sternberg cells can be so small, being scattered within the abundant fibrogranulomatous background tissue [1, 4] . Similarly, in our case, despite clinicoradiological data strongly suggesting the diagnosis of malignant lymphoma, percutaneous needle biopsy performed 3 times in total for the cervical nodal lesion and hepatic masses, failed to provide the correct diagnosis of HL. In mediastinal HL, therefore, surgical open biopsy is recommended rather than percutaneous needle biopsy when the disease is suspected [4] .
In conclusion, in patients with liver mass along with clinicoradiological features strongly suggesting malignant lymphoma, diagnosis of HL should be considered when delayed enhancement is evident on CT or MRI, or percutaneous needle biopsy reveals only inflammatory to granulomatous tissues with no malignant cells. Then, larger specimens should be obtained with surgical biopsy to confirm the diagnosis. r e f e r e n c e s
